ArticleRMD open2018
Distinguishing rheumatoid arthritis from psoriatic arthritis.
Article in RMD open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 1 synthesis or guideline pooled it, 144 citations in OpenAlex.
- Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.Rheumatology (Oxford, England) · 2021Pooled it
- The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis.RMD open · 2022Trial
- Arthralgia in Patients with Chronic Plaque Psoriasis: Practical Insights for Dermatologists.Dermatology practical & conceptual · 2026Review
- JAK/STAT inhibition reprograms T cell activation and metabolism in inflammatory arthritis patients.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Development of a confidence-based Natural Language Processing tool to identify inflammatory arthritis from non-inflammatory conditions in Rheumatology medical notes.Arthritis research & therapy · 2026Article
- Anti-inflammatory and Anti-arthritic Properties of Mucuna gigantea Plant Extracts: Establishing by Molecular Docking Study.Current computer-aided drug design · 2026Article
- Patient-reported outcome measures (PROMs) and clinical decision-making in inflammatory rheumatic conditions: a systematic review.Rheumatology advances in practice · 2026Review
- Discrimination of Rheumatoid and Psoriatic Arthritis Based on Raman and NIR Spectra Using Machine-Learning Algorithms.Molecules (Basel, Switzerland) · 2025Article
- Location and amount of joint involvement differentiates rheumatoid arthritis into different clinical subsets.NPJ digital medicine · 2025Article
- Article
- Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms.Dermatology and therapy · 2025Article
- Angiogenesis in rheumatoid Arthritis: Pathological characterization, pathogenic mechanisms, and nano-targeted therapeutic strategies.Bioactive materials · 2025Review
- Musculoskeletal Diseases: From Molecular Basis to Therapy (Volume II).Biomedicines · 2025Article
- Investigation of serum biomarkers in rheumatoid and psoriatic arthritis patients for disease-specific signatures.Arthritis research & therapy · 2025Article
- Imaging of Peripheral Arthritis: Special Focus on Differences in Inflammatory Lesions Between Rheumatoid Arthritis and Psoriatic Arthritis.Korean journal of radiology · 2025Review
- A multidimensional analysis of temporomandibular joint and ankle joint erosion in inflammatory arthritis.Frontiers in immunology · 2025Article
- Single-cell RNA sequencing of circulating immune cells supports inhibition ofFrontiers in immunology · 2025Article
- Circulating fibroblasts and neutrophils co-expressing CDH11Frontiers in immunology · 2025Article
- Glycosylation Pattern of Serum Clusterin in Psoriatic Arthritis and Rheumatoid Arthritis-The Search for New Diagnostic Glycomarkers.International journal of molecular sciences · 2024Article
- Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data.Rheumatology and therapy · 2024Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) have key differences in clinical presentation, radiographic findings, comorbidities and pathogenesis to distinguish between these common forms of chronic inflammatory arthritis. Joint involvement is typically, but not always, asymmetric in PsA, while it is predominantly symmetric in RA. Bone erosions, without new bone growth, and cervical spine involvement are distinctive of RA, while axial spine involvement, psoriasis and nail dystrophy are distinctive of PsA. Patients with PsA typically have seronegative test findings for rheumatoid factor (RF) and cyclic citrullinated peptide (CCP) antibodies, while approximately 80% of patients with RA have positive findings for RF and CCP antibodies. Although there is overlap in the pathogenesis of PsA and RA, differences are also present that affect the efficacy of treatment. In PsA, levels of interleukin (IL)-1β, IL-6, IL-17, IL-22, IL-23, interferon-γ and tumour necrosis factor-α (TNF-α) are elevated, and in RA, levels of IL-1, IL-6, IL-22, IL-33, TNF-α, chemokine ligand 11 and chemokine C-X-C motif ligand 13 are elevated. Differences in the pathogenesis of RA and PsA translate into some variances in the specificity and efficacy of therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.